Last reviewed · How we verify
Fycompa
At a glance
| Generic name | Fycompa |
|---|---|
| Also known as | Perampanel, E2007, AMPA - type Glutamate Receptor Antagonist |
| Sponsor | Eisai Inc. |
| Target | Glutamate receptor ionotropic AMPA |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Idiopathic generalized epilepsy
- Partial seizure
- Secondarily generalized seizures
Common side effects
- Dizziness
- Somnolence
- Fatigue
- Irritability
- Falls
- Nausea
- Ataxia
- Balance disorder
- Gait disturbance
- Vertigo
- Weight gain
- Headache
Key clinical trials
- Senicapoc and Perampanel for Newly Diagnosed Glioblastoma (EARLY_PHASE1)
- Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus (PHASE4)
- A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy (PHASE2)
- An Extended Access Program (EAP) for Perampanel
- Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations (PHASE1)
- PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest (PHASE2)
- A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
- A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fycompa CI brief — competitive landscape report
- Fycompa updates RSS · CI watch RSS
- Eisai Inc. portfolio CI